{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:16:23Z","timestamp":1776129383730,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors are the standard treatment for advanced hormone receptor-positive breast cancer. Although interstitial lung disease is a rare (1\u20133.3%) but serious adverse event associated with CDK4\/6 inhibitors, the incidence of interstitial lung disease in Japanese patients in the real world and the risk factors of interstitial lung disease are not clear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively investigated the incidence of interstitial lung disease in 224 patients with advanced breast cancer who received CDK4\/6 inhibitors at our hospital between 31 January 2017 and 31 January 2021. The correlation of age (&amp;gt;50 vs \u226450\u00a0years), presence or absence of previous history of interstitial lung disease, lung metastasis, smoking history and chest radiation with the development of interstitial lung disease was evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 177 cases received palbociclib, 39 cases received abemaciclib and 8 cases received both palbociclib and abemaciclib, constituting a palbociclib group (n\u00a0=\u00a0185) and an abemaciclib group (n\u00a0=\u00a047). At a median observation period of 607\u00a0days, 8.0% (18\/224) cases (13 definite and 5 probable cases) had interstitial lung disease; 6.5% (12\/185) of palbociclib-treated and 13% (6\/47) of abemaciclib-treated cases. The median time to interstitial lung disease onset was 178 (range, 14\u2013750) days. There was no significant correlation between the background factors studied and the development of interstitial lung disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The frequency of CDK4\/6 inhibitor-induced interstitial lung disease was higher than that reported in clinical trials. We did not identify any risk factors for the development of interstitial lung disease in this study, and thus, larger studies that include patient predisposition are required.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jjco\/hyac168","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T12:50:54Z","timestamp":1668430254000},"page":"105-114","source":"Crossref","is-referenced-by-count":7,"title":["Clinical features of CDK4\/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-4884","authenticated-orcid":false,"given":"Chikako","family":"Funasaka","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"},{"name":"National Cancer Center Hospital East Departments of Experimental Therapeutics, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-9064","authenticated-orcid":false,"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"},{"name":"National Cancer Center Hospital East Departments of Experimental Therapeutics, , Kashiwa, Japan"},{"name":"National Cancer Center Hospital East Departments of General Internal Medicine, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Kusuhara","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Nakao","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"},{"name":"National Cancer Center Hospital East Departments of Experimental Therapeutics, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Pharmacy, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaede","family":"Baba","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Pharmacy, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Mamishin","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Pharmacy, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Kondoh","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Harano","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"},{"name":"National Cancer Center Hospital East Departments of Experimental Therapeutics, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ako","family":"Hosono","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"},{"name":"National Cancer Center Hospital East Departments of Pediatric Oncology, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Sasaki","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Diagnostic Radiology, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikatsu","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Pharmacy, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8573-418X","authenticated-orcid":false,"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Departments of Medical Oncology, , Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"2023013012214054200_ref1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2023013012214054200_ref2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"2023013012214054200_ref3","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023013012214054200_ref4","doi-asserted-by":"crossref","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"2023013012214054200_ref5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdy012","article-title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","volume":"29","author":"Rugo","year":"2018","journal-title":"Ann Oncol"},{"key":"2023013012214054200_ref6","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"2023013012214054200_ref7","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of Abemaciclib-Associated Adverse Events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"2023013012214054200_ref8","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5\u2009years of follow-up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"key":"2023013012214054200_ref9","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2021.39.15_suppl.1072","article-title":"Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4\/6i): a systematic review and meta-analysis of phase 3 randomized controlled trials","volume":"39","author":"Jahan","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023013012214054200_ref10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment","volume":"186","author":"Raschi","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2023013012214054200_ref11","volume-title":"Japan: Ministry of Health","author":"Safety Bulletin [Internet]","year":"2019"},{"key":"2023013012214054200_ref12","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2023013012214054200_ref13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with Crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2023013012214054200_ref14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jjco\/hyy180","article-title":"Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer","volume":"49","author":"Kashiwada","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2023013012214054200_ref15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s10147-012-0489-2","article-title":"Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings","volume":"17","author":"Sakai","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"2023013012214054200_ref16","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2023013012214054200_ref17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2023013012214054200_ref18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of Palbociclib in combination with endocrine therapy for HR+\/HER2- advanced breast cancer","volume":"111","author":"Di\u00e9ras","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2023013012214054200_ref19","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s10147-021-02013-8","article-title":"Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data","volume":"26","author":"Masuda","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2023013012214054200_ref20","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.annonc.2021.03.058","article-title":"44O characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE","volume":"32","author":"Toi","year":"2021","journal-title":"Ann Oncol"},{"key":"2023013012214054200_ref21","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023013012214054200_ref22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2023013012214054200_ref23","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low\u2013expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023013012214054200_ref24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jjco\/hyn139","article-title":"Overview of Gefitinib in non-small cell lung cancer: an Asian perspective","volume":"39","author":"Jiang","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"2023013012214054200_ref25","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1016\/j.annonc.2020.08.391","article-title":"289P risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies","volume":"31","author":"Powell","year":"2020","journal-title":"Ann Oncol"},{"key":"2023013012214054200_ref26","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1002\/cnr2.1402","article-title":"Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments","volume":"5","author":"Nawa","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"2023013012214054200_ref27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s12282-020-01207-8","article-title":"Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan","volume":"28","author":"Chen","year":"2021","journal-title":"Breast Cancer"},{"key":"2023013012214054200_ref28","doi-asserted-by":"crossref","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"2023013012214054200_ref29","first-page":"Cd010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023013012214054200_ref30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14737140.2019.1674651","article-title":"Can CDK4\/6 inhibitors cause fatal lung injury?","volume":"19","author":"Jazieh","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"2023013012214054200_ref31","first-page":"162","article-title":"Fatal Palbociclib -related interstitial pneumonitis","volume":"3","author":"Ofer","year":"2019","journal-title":"Arch Clin Med Case Rep"},{"key":"2023013012214054200_ref32","first-page":"A5546-A","volume-title":"C43 drug induced lung disease: Case reports","author":"Malik"},{"key":"2023013012214054200_ref33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10549-017-4606-9","article-title":"A single institution experience with palbociclib toxicity requiring dose modifications","volume":"168","author":"Gong","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2023013012214054200_ref34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000507647","article-title":"Ribociclib-induced pneumonitis: a case report","volume":"16","author":"Algwaiz","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"2023013012214054200_ref35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3332\/ecancer.2021.1245","article-title":"CDK 4\/6 inhibitor induced lung injury: a case report and review of literature","volume":"15","author":"Mathew","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"2023013012214054200_ref36","first-page":"e8929\u2013e","article-title":"Palbociclib-induced pneumonitis: a case report and review of the literature","volume":"12","author":"Sarkisian","year":"2020","journal-title":"Cureus"},{"key":"2023013012214054200_ref37","article-title":"CDK4\/6 inhibitor-induced pneumonitis: a case report and review of the literature","volume":"24","author":"Wilgus","year":"2020","journal-title":"ProcUCLA Health"},{"key":"2023013012214054200_ref38","volume-title":"Japan: Pharmaceuticals and medical deviced agency","author":"The Japanese package insert of Verzenio\u00ae Tablets [Internet]","year":"2021"},{"key":"2023013012214054200_ref39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12931-020-01433-w","article-title":"CDK4\/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis","volume":"21","author":"Birnhuber","year":"2020","journal-title":"Respir Res"},{"key":"2023013012214054200_ref40","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.pan.2020.04.011","article-title":"Inhibition of Rb phosphorylation leads to H(2)S-mediated inhibition of NF-kB in acute pancreatitis and associated lung injury in mice","volume":"20","author":"Sundar","year":"2020","journal-title":"Pancreatology"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/2\/105\/48945753\/hyac168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/2\/105\/48945753\/hyac168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T21:25:56Z","timestamp":1701206756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/2\/105\/6827179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,14]]},"published-print":{"date-parts":[[2023,1,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac168","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2022,11,14]]}}}